Page 4 - John Corboy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How this relates to infection outcomes or risk of infecting others is unknown

To treat or not to treat? I’ve been treated with four DMTs in my four decades of living with MS. The first was Avonex (interferon beta 1a) in 1996. Then came Tysabri (natalizumab) and Aubagio (teriflunomide). The most recent was Lemtrada (alemtuzumab) in late 2016. I believe Lemtrada was the most effective of the four, and I was 68 when this treatment began. Lemtrada halted my progression and improved some of my symptoms. But some neurologists won’t prescribe a DMT for someone older than 50 or 60. There is some indication that the older you get, the less your MS will progress, so those do...

email article Antibody responses after SARS-CoV-2 infection were reduced in multiple sclerosis (MS) patients on ocrelizumab (Ocrevus) compared with other MS patients, but T-cell responses were not, preliminary data from a New York study suggested. Antibody detection varied but T-cell levels were similar for patients with COVID-19 and MS regardless of the disease-modifying treatment they used, reported Ilya Kister, MD, of NYU Langone Health in New York City, at the Emerging Science session of the American Academy of Neurology virtual meeting. "The top-line result of our study is that MS ...